Analysts point to Definium psychedelic’s MDD efficacy on Phase III success
Following the first late-stage win in a Phase III programme evaluating Definium Therapeutics’ lysergic acid diethylamide (LSD)-based psychedelic in major …
Post
-
-
MSD’s anti-TL1A mAb from $10.8bn acquisition wins in Phase III trial
MSD’s investigational humanised monoclonal antibody targeting tumour necrosis factor-like cytokine 1A (TL1A), which it acquired during a $10.8bn buyout of …
-
GondolaBio reports positive data from Phase IIa trial of PORT-77
GondolaBio has reported positive results from its Phase IIa GATEWAY study of PORT-77, an investigational oral ABCG2 inhibitor, which aims …
-
Medidata establishes Academic Site Advisory Board for clinical trials
Dassault Systèmes brand Medidata has announced the formation of its Academic Site Advisory Board to address the distinct operational and …
-
UK MHRA sets path for puberty blocker trial to continue
The Medicines and Healthcare products Regulatory Agency (MHRA) has cleared an investigator-led trial investigating puberty blockers in children and young people …
-
Kither Biotech concludes Phase I study of KIT2014
Kither Biotech has completed its Phase I clinical trial assessing KIT2014, an inhaled peptide therapy designed for the treatment of …
-
Post-marketing oncology studies: Enabling faster recruitment and lower costs
Post-marketing approval studies in clinical research for cancer typically suffer from poor engagement and protracted timelines – driving up costs …
-
First participant receives Evategrel in CureGene’s trial
CureGene Pharmaceutical has dosed the first participant in its pivotal clinical trial of Evategrel (CG-0255), a next-generation antiplatelet therapy, in …
-
Congressman proposes draft legislation to accelerate US clinical trials
A draft legislation aimed at accelerating drug discovery and clinical trials has been proposed in the US. Democratic Congressman Jake Auchincloss, …
-
Eye-opening study highlights connection between HPV and uveitis
Uveitis is the leading cause of preventable blindness in adults aged 20–60 years, and while some details are known about …
-
Biopharma industry confidence at highest in years despite geopolitical headwinds
Biopharma executives’ confidence in the industry has reached its highest point in four years, reflecting a successful navigation through a …
-
Shionogi and F2G report positive top line data from Phase III OASIS study
Shionogi and F2G have reported positive top line data from the global OASIS Phase III study evaluating oral antifungal drug …
-
MAIA activates new site for THIO-101 Phase II trial
MAIA Biotechnology has activated a new US site, the Winship Cancer Institute of Emory University, and opened patient enrolment for …
-
How wearables can unlock their full potential in clinical research
In recent years, wearable devices that track sleep, activity, heart rate, and recovery through smartwatches, fitness bands, and rings have …
-
Novocure’s Optune Gio fails to show benefit at earlier stage
Novocure’s stock has dropped more than 15% after its Phase III glioblastoma study of Optune Gio failed to show benefit …
